Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

TherapeuticsMD
→
Mayne Pharma

License/Asset Acquisition · Cash (license/asset) · MYX · announced Dec 4, 2022

View in network
  1. Announced

    Dec 4, 2022

  2. Closed

    Dec 30, 2022

Economics

Cash (license/asset)()

Pre-deal · pre-deal mark: 2022, year precision · rounding grid ±$100M · Mayne Pharma press release — TherapeuticsMD acquisition, 2023

$140M upfront license + $13.1M working capital + up to $30M milestones + 20-year royalties

Target

TherapeuticsMD

Reproductive Health · Clinical / therapeutic

HQ Boca Raton, FL · Founded 2008

Women's health hormone therapy — BIJUVA (bio-identical estradiol/progesterone for menopause), ANNOVERA (contraceptive vaginal ring), IMVEXXY (estradiol vaginal inserts); $153M total consideration

  • Business Wire — TherapeuticsMD press release (Jan 3, 2023)
  • SEC EDGAR — TherapeuticsMD 8-K (Dec 30, 2022)

Acquirer

Mayne Pharma (MYX)

Reproductive Health

HQ Melbourne, Australia

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Exclusive US rights to BIJUVA (menopause), ANNOVERA (contraception), and IMVEXXY (vaginal atrophy) — establishes Mayne Pharma in women's health hormone therapy

Evidence ladder

Dual-source corroborationValue disclosed
  1. Secondary (press / IR)

    Business Wire — TherapeuticsMD press release (Jan 3, 2023)

  2. Primary (regulatory / filing)

    SEC EDGAR 8-K (Jan 3, 2023

    SEC EDGAR filings (ticker locator)
  3. Tertiary (trade / analyst)

    closing effective Dec 30, 2022)

  4. Primary (regulatory / filing)

    SEC EDGAR 8-K EX-99.1 (TherapeuticsMD, Dec 4, 2022 — definitive agreements) https://www.sec.gov/Archives/edgar/data/25743/000119312522298002/d409080dex991.htm

    Open source
  5. Primary (regulatory / filing)

    SEC EDGAR 8-K (TherapeuticsMD, Jan 3, 2023 — closing effective Dec 30, 2022) https://www.sec.gov/Archives/edgar/data/25743/000119312523000222/d417698d8k.htm

    Open source

Limitations

  • $140M upfront license + $13.1M working capital + up to $30M milestones + 20-year royalties
  • Pre-deal valuation sourced from: Mayne Pharma press release — TherapeuticsMD acquisition, 2023. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Reproductive Health

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Insufficient disclosed data

No verified Reproductive Health deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.

Other verified deals by Mayne Pharma

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Mayne Pharma are already listed above, or none are in the dataset.

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — TherapeuticsMD (Reproductive Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 5 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.